These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8993509)

  • 1. Clinical pharmacology and pharmacodynamics of irinotecan. A review.
    Chabot GG
    Ann N Y Acad Sci; 1996 Dec; 803():164-72. PubMed ID: 8993509
    [No Abstract]   [Full Text] [Related]  

  • 2. Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
    Ratain MJ
    Clin Cancer Res; 2000 Sep; 6(9):3393-4. PubMed ID: 10999719
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
    Mross K; Steinbild S; Baas F; Reil M; Buss P; Mersmann S; Voliotis D; Schwartz B; Brendel E
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):618-9. PubMed ID: 14692719
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical studies of camptothecin and derivatives.
    Soepenberg O; Sparreboom A; Verweij J
    Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
    [No Abstract]   [Full Text] [Related]  

  • 5. Design, synthesis and development of novel camptothecin drugs.
    Liew ST; Yang LX
    Curr Pharm Des; 2008; 14(11):1078-97. PubMed ID: 18473856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Ann N Y Acad Sci; 1996 Dec; 803():173-80. PubMed ID: 8993510
    [No Abstract]   [Full Text] [Related]  

  • 7. UGT1A and irinotecan toxicity: keeping it in the family.
    Hoskins JM; McLeod HL
    J Clin Oncol; 2009 May; 27(15):2419-21. PubMed ID: 19364959
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of the clinical experience with irinotecan (CPT-11).
    Horowitz RW; Wadler S; Wiernik PH
    Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan for metastatic colorectal cancer.
    Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical pharmacology of camptothecins.
    Iyer L; Ratain MJ
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan-induced dysarthria.
    Baz DV; Bofill JS; Nogueira JA
    J Natl Cancer Inst; 2001 Sep; 93(18):1419-20. PubMed ID: 11562394
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?
    Wagner LM
    Pediatr Blood Cancer; 2010 May; 54(5):661-2. PubMed ID: 20108333
    [No Abstract]   [Full Text] [Related]  

  • 13. [Topoisomerase I inhibitor (irinotecan hydrochloride)].
    Inoue S; Hassan MK; Kanetoshi A
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():456-60. PubMed ID: 15658362
    [No Abstract]   [Full Text] [Related]  

  • 14. [Irinotecan hydrochloride for treatment of advanced breast cancers].
    Morimoto K; Kou M; Kinoshita H
    Nihon Rinsho; 2000 Apr; 58 Suppl():265-70. PubMed ID: 11026005
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Irinotecan and liver dysfunctions].
    Sablin MP; Le Tourneau C; Faivre S; Raymond E
    Therapie; 2007; 62(2):111-5. PubMed ID: 17582311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
    de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).
    Dodds HM; Rivory LP
    Br J Pharmacol; 2001 Sep; 134(2):448-50. PubMed ID: 11564665
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
    Ohe Y; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Kojima A; Kunikane H; Okamoto H; Karato A; Ohmatsu H
    J Natl Cancer Inst; 1992 Jun; 84(12):972-4. PubMed ID: 1321253
    [No Abstract]   [Full Text] [Related]  

  • 20. Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?
    Gasparini G; D'Andrea MR; Toffoli G
    J Clin Oncol; 2010 Apr; 28(12):e199. PubMed ID: 20308659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.